The marketing authorisation for the vaccine, Vaxzevria, in the European Union was withdrawn at the company’s request this week as the vaccine is no longer manufactured or supplied, Astra said in a statement. The decision was not related to safety reasons, it said.
AZ vaccine
AstraZeneca Plc pulled its Covid-19 vaccine from the market due to lack of demand for a shot that initially raised hopes it would play a key role in protecting the world against the virus.
The marketing authorisation for the vaccine, Vaxzevria, in the European Union was withdrawn at the company’s request this week as the vaccine is no longer manufactured or supplied, Astra said in a statement. The decision was not related to safety reasons, it said.
Astra’s vaccine, which was developed with Oxford University, was initially offered on a not-for-profit basis and was seen as a win for Britain, with then-Prime Minister Boris Johnson publicly receiving his first dose.
However, the rollout was plagued by concerns about its efficacy and safety, starting with French President Emmanuel Macron calling it “quasi-ineffective” in older adults shortly after it was approved in the EU.
AZ vaccine
The vaccine, which didn’t require ultra-cold storage as some of the rival Covid-19 shots did, was seen as a good option to inoculate large portions of the globe. More than three billion doses were supplied.
After Macron’s comments, a bigger blow came when regulators began investigating the vaccine’s link to very rare cases of unusual blood clots. Regulators ultimately found that the risk-benefit of the vaccine was positive.
As countries looked to procure booster shots for the populations, Astra’s vaccine was sidelined in favour of shots using mRNA technology, especially one developed by a partnership of BioNTech SE and Pfizer Inc. Astra faces legal challenges from families of patients who died after receiving the vaccine.
Companies including Pfizer and Moderna Inc. have since developed updated Covid-19 vaccines targeting newer variants. Astra said that this has led to “a surplus of available updated vaccines” and a decline in demand for its shot.